RxDoctor Payments Data

Joe Vongvorachoti, MD

Physical Medicine & Rehabilitation · New York, NYNPI 1457550519

Payments from drug & device makers

$490in general payments, 2019–2025

Across 16 payments — averaging $30.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$154
  • Boston Scientific$128
  • Johnson & Johnson$74
  • Pacira Therapeutics, Inc.$38
  • Pfizer$37
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$32
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$490100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$490 in reported general payments places this provider in the 65th percentile of 872 physical medicine & rehabilitation providers in New York.

See all physical medicine & rehabilitation providers in New York

Medicare billing

Part B allowed, 2024
$238,152
Medicare patients
288
Services billed
2,787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide14$25,486
Diclofenac Sodium17$13,379
Xtampza ErOxycodone Myristate32$10,774
OxycontinOxycodone Hcl24$6,406
MovantikNaloxegol Oxalate11$5,063
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen139$1,880
Gabapentin210$1,473
Pregabalin91$1,180
Celecoxib82$1,058
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53$555
Morphine Sulfate ErMorphine Sulfate22$364
Baclofen29$236
Oxycodone Hcl18$204
Methocarbamol17$185
Meloxicam81$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$32$25,48614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 872 physical medicine & rehabilitation providers in New York.

Other physical medicine & rehabilitation in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →